Identification
Personal identification
- Full name
- Cecília Maria Pereira Rodrigues
Citation names
- Rodrigues, CMP
- Rodrigues, CM
- Rodrigues, C
Author identifiers
- Ciência ID
- DC18-39A7-F287
- ORCID iD
- 0000-0002-4829-754X
- Researcher Id
- M-3572-2013
- Scopus Author Id
- 7202508239
Email addresses
- cmprodrigues@ff.ulisboa.pt (Professional)
Telephones
- Fax
-
- 217946491 (Professional)
- Telephone
-
- 217946490 (Professional)
Addresses
- iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa. Av. Prof. Gama Pinto, 1649-003, Lisboa, Lisboa, Portugal (Professional)
Websites
- https://imed.ulisboa.pt/cv/cecilia-maria-pereira-rodrigues/ (Scholar)
- http://www.imed.ulisboa.pt/ (Scholar)
- http://www.ff.ul.pt/ (Scholar)
Knowledge fields
- Medical and Health Sciences - Basic Medicine - Pharmacology and pharmacy
Languages
Language | Speaking | Reading | Writing | Listening | Peer-review |
---|---|---|---|---|---|
Portuguese (Mother tongue) | |||||
English | Proficiency (C2) | Proficiency (C2) | Proficiency (C2) | Proficiency (C2) | Proficiency (C2) |
French | Intermediate (B1) | Upper intermediate (B2) | Intermediate (B1) | Upper intermediate (B2) | Intermediate (B1) |
Spanish; Castilian | Upper intermediate (B2) | Upper intermediate (B2) | Intermediate (B1) | Upper intermediate (B2) | Upper intermediate (B2) |
Education
Degree | Classification | |
---|---|---|
2005/09/13
Concluded
|
Pharmacy (Título de Agregado)
Major in Biological Sciences
Universidade de Lisboa Faculdade de Farmácia, Portugal
"Modulation of Apoptosis by Bile Acids. Lição de síntese apresentada em provas de habilitação ao título de Agregada no 2º
Grupo de Ciências Biológicas da Faculdade de Farmácia da Universidade de Lisboa" (THESIS/DISSERTATION)
|
Approved |
1996/03/01
Concluded
|
Pharmacy (Doutoramento)
Major in Biochemistry
Universidade de Lisboa Faculdade de Farmácia, Portugal
"The metabolism of ursodeoxycholic acid: basic and clinical studies" (THESIS/DISSERTATION)
|
Approved with Distinction and Honor |
1992
Concluded
|
Pharmaceutical Sciences (Licenciatura)
Universidade de Lisboa Faculdade de Farmácia, Portugal
"n/a" (THESIS/DISSERTATION)
|
Excellent: Eighteen (18/20) |
Affiliation
Science
Category Host institution |
Employer | |
---|---|---|
1996 - 1999 | Postdoc (Research) | University of Minnesota, United States |
University of Minnesota, United States | ||
1992 - 1995 | Researcher (Research) | University of Cincinnati, United States |
Teaching in Higher Education
Category Host institution |
Employer | |
---|---|---|
2009 - Current | Full Professor (University Teacher) | Universidade de Lisboa Faculdade de Farmácia, Portugal |
Universidade de Lisboa Faculdade de Farmácia, Portugal | ||
2006 - 2009 | Associate Professor (University Teacher) | Universidade de Lisboa Faculdade de Farmácia, Portugal |
Universidade de Lisboa Faculdade de Farmácia, Portugal | ||
2004 - 2006 | Assistant Professor (University Teacher) | Universidade de Lisboa Faculdade de Farmácia, Portugal |
Universidade de Lisboa Faculdade de Farmácia, Portugal | ||
1999 - 2004 | Assistant (University Teacher) | Universidade de Lisboa Faculdade de Farmácia, Portugal |
Universidade de Lisboa Faculdade de Farmácia, Portugal |
Positions / Appointments
Category Host institution |
Employer | |
---|---|---|
2021/10/01 - 2025/09/30 | Vice-Rector | Universidade de Lisboa, Portugal |
Universidade de Lisboa, Portugal | ||
2021/01/01 - 2021/10/01 | Organic Unit President | Universidade de Lisboa Faculdade de Farmácia, Portugal |
Universidade de Lisboa Faculdade de Farmácia, Portugal | ||
2013 - 2020 | Organic Unit Director | Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal |
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal | ||
2007 - 2020 | Manager of Laboratory, Institute, Museum, Centre or Observatory | Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal |
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal | ||
2011 - 2018 | Organic Unit President | Universidade de Lisboa Faculdade de Farmácia, Portugal |
Universidade de Lisboa Faculdade de Farmácia, Portugal |
Projects
Grant
Designation | Funders | |
---|---|---|
1996 - 1999 | Molecular Studies of Ursodeoxycholic Acid Therapeutic Effects, University of Minnesota, Minneapolis, MN, USA
Bolsa BPD FCT
Post-doc Fellow
University of Minnesota, United States
|
Fundação para a Ciência e a Tecnologia
Concluded
|
1992 - 1995 | The Metabolism of Ursodeoxycholic Acid: Basic and Clinical Studies, University of Cincinnati, Cincinnati, OH, USA
Bolsa BD FCT
PhD Student Fellow
University of Cincinnati Academic Health Center, United States
|
Fundação para a Ciência e a Tecnologia
Concluded
|
1990 - 1992 | Centro de Metabolismos e Genética, University of Lisbon, Lisbon, Portugal
Bolsa BII Instituto Nacional de Investigação Científica (INIC)
Scientific Initiation Fellow
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
Contract
Designation | Funders | |
---|---|---|
2024/01/01 - Current | Total of ca. 70 projects (Principal Investigator in >35, generating ca. 20M Euro)
Principal investigator
|
|
2022/01/01 - 2024/12/31 | Translating RIPK3 Signalling into Application in Metabolic Liver Disease
PTDC/MED-FAR/3492/2021
Principal investigator
Associação da Faculdade de Farmácia para a Investigação e Desenvolvimento, Portugal
|
Ongoing
|
2021/11/01 - 2024/10/30 | RIPK3 Biology and Targeting in Metabolic Liver Disease
LCF/PR/HR21/52410028
Principal investigator
Associação da Faculdade de Farmácia para a Investigação e Desenvolvimento, Portugal
|
Fundação para a Ciência e a Tecnologia
Ongoing
|
2017 - 2024 | LITMUS - Liver Investigation: Testing Marker Utility in Steatohepatitis
IMI2 116125-2 H2020
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
European Commission
Ongoing
|
2017/01 - 2021/12 | FOIE GRAS - Bioenergetic remodeling in the pathophysiology and treatment of non-alcoholic fatty liver disease
H2020 MSCA-ITN-ETN 2016 European Commission
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
European Commission
Ongoing
|
2018 - 2021 | LiverBTT - Non-alcoholic Fatty Liver Disease: Emerging Biomarkers, Targets and Therapies
PTDC/MED-FAR/29097/2017
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e Tecnologia
Ongoing
|
2018 - 2021 | Exosomal Fat-Liver Axis in Non-Alcoholic Fatty Liver Disease: Function and Modulation
PTDC/MED-PAT/31882/2017
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Ongoing
|
2018 - 2021 | Metabolic Control of Neural Repair by Diet and Gut Microbiome during Aging
PTDC/MED-NEU/29650/2017
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Ongoing
|
2018 - 2021 | Nanoformulated Hybrid Molecules For Specific Targeting Melanoma Metastasis
PTDC/MED-QUI/31721/2017
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Ongoing
|
2018 - 2021 | Drug discovery for p53 PPi-targets
PTDC/QUI-QOR/29664/2017
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Ongoing
|
2018 - 2021 | Targeting aquaporin-3 as a novel therapeutic approach for melanoma
PTDC/BTM-SAL/28977/2017
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Ongoing
|
2018 - 2021 | Tricks or Treats? Toward Selective Organoruthenium(II) Glycoconjugated Anticancer Agents
PTDC/MED-QUI/31468/2017
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Ongoing
|
2017 - 2021 | mitoFOIE GRAS - Non-invasive Profiling of Mitochondrial Function in Non-Alcoholic Fatty Liver Disease
H2020-MSCA-RISE-2016 734719
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
H2020-MSCA-RISE-2016
Ongoing
|
2017 - 2020 | POINT4PAC - Precision Oncology by Innovative Therapies and Technologies
COMPETE 2020 SAICTPAC/0019/2015
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Ongoing
|
2017 - 2019 | Targeting the NAFLD-HCC continuum with bile acid-activated receptor agonists and microRNAs
Intercept 2017
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Intercept Pharmaceuticals
Concluded
|
2016 - 2019 | New Drugs to Treat Non-alcoholic Fatty Liver and Progression to Cancer
PTDC/BIM-MEC/0895/2014
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2015 - 2018 | High Throughput Screening With AstraZeneca's Compound library
AZ HTS 2015
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
AstraZeneca UK Ltd
Concluded
|
2015 - 2017 | Role of Mitofusin 2 in Non-Alcoholic Fatty Liver Disease and Targeting by microRNAs
Gilead Science International 2015
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Gilead Sciences International Ltd
Concluded
|
2013 - 2016 | Treat Liver Disease by Targenting Hepatocyte Necroptosis
HMSP-ICT/0018/2011
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Harvard Medical School Fundação para a Ciência e a Tecnologia Concluded
|
2013 - 2015 | New Therapeutic Targets to Control Viral Hepatitis
Gilead Science 2013
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Gilead Sciences Lda
Concluded
|
2013 - 2015 | Driving Mitochondrial Effectors of Apoptosis Toward Neural Differentiation
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2012 - 2015 | NecroPT - Targeting Hepatocyte Necroptosis to Treat Liver Diseases
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2012 - 2015 | Interaction of bile acids with lipid membranes: creating a shield or bursting the bubble.
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2012 - 2015 | Oceanic Treasures - Oceanic sediments from the Madeira Archipelago: a new source of innovative and bioactive compounds
PTDC/QUI-QUI/119116/2010
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2012 - 2015 | Functional compatibility of the replication complex as determinant of virulence in influenza virus
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2012 - 2015 | Aiming at microRNA-21 and bile acid activated receptors in non-alcoholic fatty liver disease pathogenesis: two bullets for
one murder?
PTDC/BIM-MEC/0873/2012
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2012 - 2014 | Preventing Memory Loss in Alzheimer's Disease: Underlying Mechanisms and Therapeutic Targets of Tauroursodeoxycholic Acid
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2011 - 2014 | Modulation of amyloid beta-induced neuronal toxicity via JNK: a novel role for tauroursodeoxycholic acid
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2011 - 2013 | Targeting microRNA-34, a Potential Link between Apoptosis and Nonalcoholic Fatty Liver Disease Pathogenesis
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2010 - 2013 | The influence of bile acids in malaria hepatic infection
PTDC/SAU-MII/099118/2008
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2010 - 2012 | Prevalence and severity of fatty liver in morbid obesity: correlation and mechanisms related with the role of ectopic fat
in insulin resistance
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2009 - 2012 | Understanding microRNA Profiles and Cellular Functions in Colorectal Cancer
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2009 - 2012 | Exploring New Roles for Endogenous Bile Acids and microRNAs in Modulating Liver Regeneration
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2009 - 2011 | Advancing the field of drug delivery - combined targeted treatments against human breast cancer and human leukemia (The OncotargetNanoMed
network)
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2009 - 2011 | Modulation of liver regeneration by bile acids: role of miRNAs
SPG 2008
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Sociedade Portuguesa de Gastrenterologia
Concluded
|
2008 - 2011 | Linking Fibrillogenesis and the Apoptosis Induced by Amyloid-beta Mutant Peptides
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2008 - 2011 | Membrane receptors and mediators involved in plastic changes induced by neuronal insults: implications for neuroprotection
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2007 - 2010 | Neurodegeneration in Alzheimer’s Disease Transgenic Mice: Role of Apoptosis and its Modulation
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2007 - 2009 | Evaluation of the protective role of Glutathione S-Transferase pi against MPTP neurotoxicity
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2007 - 2009 | Studies on genetic and physiological characterization of sheep adaptation to food restriction
Researcher
Universidade de Lisboa Faculdade de Medicina Veterinária, Portugal
|
Universidade de Coimbra
Concluded
|
2007 - 2009 | Correlation between aggregation, fibril formation and apoptosis induced by APP missense mutations
Pfizer 2007
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Pfizer Biofarmacêutica Sociedade Unipessoal Lda
Concluded
|
2007 - 2009 | Isolation, characterization and application of a unique population of liver derived stem cells
ROCHE 2017
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Roche Farmaceutica Quimica Lda
Concluded
|
2004 - 2009 | Apoptosis and inflammatory response in colorectal carcinogenesis: interaction between p53, ß-catenin and TGFß pathways in
prognosis and resistance to therapy
FCG/68796/2004
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação Calouste Gulbenkian
Concluded
|
2007 - 2008 | Tauroursodeoxycholic Acid Protection of Compression Spinal Cord Injury: Targeting Cell Survival Cascades
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2005 - 2008 | Bile Acid Mediated Inhibition of Neuronal Apoptosis
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2006 - 2007 | Basic cellular mechanisms of anti-apoptotic signaling by bile acids
FCG Estímulo 2005
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação Calouste Gulbenkian
Concluded
|
2005 - 2007 | Basic mechanisms of apoptosis in cells expressing an Alzheimer’s disease-associated double mutation
FLAD/L-V-595/2004
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação Luso-Americana
Concluded
|
2003 - 2007 | Signaling events in tauroursodeoxycholic acid protection of amyloid ß-peptide-induced neuronal death
POCTI/BCI/44929/2002
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
2003 - 2005 | Colorectal cancer and apoptosis: nutrition and cellular metabolism as risk factors
SPG2002
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Sociedade Portuguesa de Gastrenterologia
Concluded
|
2002 - 2004 | Pathogenic mechanisms of injury in human alcoholic and non-alcoholic steatohepatitis: from oxidative stress to cell death
by apoptosis
SPGG2001
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Sociedade Portuguesa de Gastrenterologia
Concluded
|
2000 - 2002 | Role of mitochondria in bile acid-, bilirubin- and amyloid ß-peptide-induced apoptosis and protective effect of ursodeoxycholic
acid and its conjugates
EASLFellow2000
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
European Association for the Study of the Liver
Concluded
|
1999 - 2001 | Mechanisms of cell injury by glycochenodeoxycholic acid, bilirubin, and ß-amyloid. Role of ursodeoxycholic acid in preventing
apoptosis by inhibiting mitochondrial cytochrome c release and caspase activation
PRAXIS/C/SAU/14311/98
Principal investigator
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
|
Fundação para a Ciência e a Tecnologia
Concluded
|
Outputs
Publications
Book |
|
Book chapter |
|
Conference paper |
|
Journal article |
|
Intellectual property
Patent |
|
Other
Other output |
|
Activities
Oral presentation
Presentation title | Event name Host (Event location) |
|
---|---|---|
2020/01/01 | Total of ca. 250 oral communications (> 100 international) | |
2020 | Circulating miR-335 is reduced in Parkinson’s disease patients and its overexpression negatively regulates inflammatory events | AD/PD Meeting 2020
AD/PD (Viena, Germany)
|
2019 | Diet-associated gut microbiota metabolites dictate mitochondrial stress as a key regulator of adult neurogenesis. | 11th International Meeting of the Portuguese Society for Stem Cells and Cell Therapies
Portuguese Society for Stem Cells and Cell Therapies (Lisboa, Portugal)
|
2019 | Discovery of colon cancer stem cell inhibitors by high-throughput screening in a 3D spheroid model. | 11th International Meeting of the Portuguese Society for Stem Cells and Cell Therapies
Portuguese Society for Stem Cells and Cell Therapies (Lisboa, Portugal)
|
2019 | Tuning cell death in neuroinflammation. | 53rd Annual Scientific Meeting of the European Society for Clinical Investigation
European Society for Clinical Investigation (Coimbra, Portugal)
|
2019 | RIP3 deficiency remodels mitochondrial bioenergetics and function in experimental NAFLD | 53rd Annual Scientific Meeting of the European Society for Clinical Investigation
European Society for Clinical Investigation (Coimbra, Portugal)
|
2019 | High-throughput phenotypic screening of colon cancer stem cell inhibitors using tumourspheres. | 27th United European Gastroenterology Week
United European Gastroenterology (Barcelona, Spain)
|
2019 | miRNA-21 signals through a gut-liver axis to regulate experimental cholestasis. | The International Liver Congress European Association for the Study of the Liver
European Association for the Study of the Liver (Vienna, Germany)
|
2019 | Genetic deletion of RIP3 abrogates dopaminergic neuronal death in the MPTP-mouse model of Parkinson’s disease | AD/PD 2019, 14th International Conference on Alzheimer's and Parkinson's DiseasesAD/PD 2019
AD/PD 2019 (Lisboa, Portugal)
|
2019 | Nanoformulated hybrid molecules with high in vitro and in vivo potential against melanoma | EUFEPS Annual Meeting 2019
EUFEPS (Frankfurt, Germany)
|
2019 | FXR mode of action dans le maladie chroniques du foie | 85e Journées Scientifiques de l’APEF. 20e Journée de Formation Médicale Continue en Hétatologie
APEF (Marselha, France)
|
2019 | Metabolic liver disease | ICAN Series 2019. Cardiometabolic disease interfaces: defining new paradigms
ICAN (Paris, France)
|
2019 | Genetics and epigenetics of NAFLD progression | Symposium Molecular basis of non-alcoholic fatty liver disease progression
V UIMP-IBIS School of Biomedicine (Sevilha, Spain)
|
2018 | Muscle miR-34a is activated during NAFLD progression, promoting insulin resistance and mitochondrial dynamics dysfunction | 26th United European Gastroenterology Week
United European Gastroenterology (Viena, Germany)
|
2018 | Deregulation of small intestine permeability by miRNA-21 in liver disease. | 9th biennial meeting for the Society for Free Radical Research International
Society for Free Radical Research International (Lisboa, Portugal)
|
2017 | miRNAs as biomarkers and targets. | European Association for the Study of the Liver, NAFLD Summit
European Association for the Study of the Liver (Roma, Italy)
|
2017 | miRNAs as biomarkers and regulators of liver disease. | 51st Conference of the European Society for Clinical Investigation
European Society for Clinical Investigation (Genova)
|
2017 | Molecular markers in colorectal cancer: miRNAs and its clinical implications. | Leaping Forward Oncology – International Clinical Congress
(Lisboa, Portugal)
|
2017 | miR-21 ablation and obeticholic acid ameliorate NASH in mice | Keystone Symposium Bile Acid Receptors as Signal Integrators in Liver and Metabolism
Keystone Symposia (Monterey, United States)
|
2016 | Selective targeting of FXRa isoforms by novel bile acid derivatives is associated with inhibition of lipotoxicity in liver cells | 24th United European Gastroenterology Week
United European Gastroenterology (Viena, Germany)
|
2016 | Activation of necroptosis in human and experimental cholestasis | 24th United European Gastroenterology Week
United European Gastroenterology (Viena, Germany)
|
2016 | The role of miRNA-145 in colon cancer stem cell-like cells. | 24th United European Gastroenterology Week
United European Gastroenterology (Viena, Germany)
|
2016 | Improving metabolic parameters in NAFLD by targeting nuclear receptors | 24th United European Gastroenterology Week
United European Gastroenterology (Viena, Germany)
|
2016 | RIP3 regulates acute cholestasis-associated necroptotic signaling and cell death. | The International Liver Congress European Association for the Study of the Liver
European Association for the Study of the Liver (Barcelona, Spain)
|
2015 | Alcoholic and non-alcoholic steatohepatitis: Mechanisms of cell death and clinical relevance | XX Annual Conference “Hepatology Today 2015” EASL/RSLS Symposium
RSLS/EASL (Moscovo, Russia)
|
2015 | Dual targeting of microRNA-21 and FXR ameliorates NAFLD pathogenesis in mice. | 23rd United European Gastroenterology Week
United European Gastroenterology (Barcelona, Spain)
|
2015 | MEK5/ERK5 signalling controls colon cancer cell sensitivity to 5-fluorouracil through a p53 dependent mechanism | 23rd United European Gastroenterology Week
United European Gastroenterology (Barcelona, Spain)
|
2015 | Contribution of miRNA-143 and miRNA-145 to cetuximab-mediated cellular cytotoxicity in colon cancer cells | 23rd United European Gastroenterology Week
United European Gastroenterology (Barcelona, Spain)
|
2015 | The dual role of necroptosis in cholestasis | 23th Euroconference on Apoptosis “Death Pathways and Beyond”
European Cell Death Organization (Genebra, Switzerland)
|
2014 | MEK5/ERK5 signalling activates NF-¿B and promotes a more aggressive phenotype in human colon cancer cells | 22nd United European Gastroenterology Week
United European Gastroenterology (Viena, Germany)
|
2014 | Deoxycholic acid trigers primary rat hepatocyte apoptosis in a dose-dependent manner by hampering caspase-2/NF-¿¿-associated activation of miRNA-21 | 64th Annual Meeting of the American Association for the Study of Liver Diseases
American Association for the Study of Liver Diseases (Washington, United States)
|
2014 | Moving Forward: Discussions on implications for patients from basic research, Joint Workshop EASL-I-PSC-G | The International Liver Congress European Association for the Study of the Liver
European Association for the Study of the Liver (Londres, United Kingdom)
|
2013 | Bile acids: hepatotoxicity and hepatoprotection. | The International Liver Congress European Association for the Study of the Liver
European Association for the Study of the Liver (Londres, United Kingdom)
|
2013 | miR-143 and miR-145 overexpression improve the response to cetuximab in HCT116 KRAS mutant colon cancer cells | 21st United European Gastroenterology Week
United European Gastroenterology (Berlim, Germany)
|
2013 | MEK5/ERK5 signalling modulates cell proliferation and survival and influences sensitivity to 5-fluorouracil in colon cancer cells | 21st United European Gastroenterology Week
United European Gastroenterology (Berlim, Germany)
|
2013 | MEK5/ERK5 expression is increased in colon cancer adenomas and adenocarcinomas, and MEK5/ERK5 signalling accelerates cell cycle progression and migration in SW620 colon cancer cells | 21st United European Gastroenterology Week
United European Gastroenterology (Berlim, Germany)
|
2013 | Skeletal muscle miRNAs and correlation with liver miRNAs in non-alcoholic fatty liver disease, and targeting by tauroursodeoxycholic acid in vitro | 21st United European Gastroenterology Week
United European Gastroenterology (Berlim, Germany)
|
2013 | JNK1-dependent modulation of miR-34a contributes to apoptosis induced by deoxycholic acid in primary rat hepatocytes | The International Liver Congress European Association for the Study of the Liver
European Association for the Study of the Liver (Amsterdão)
|
2012 | miR-34a/SIRT1/p53 signaling is activated in human non-alcoholic fatty liver disease and target by ursodeoxycholic acid in the rat liver via inhibition of p53 transactivation | 20th United European Gastroenterology Week
United European Gastroenterology (Amsterdão)
|
2012 | Apoptotic miRNA-21/PDCD4 signaling in rat hepatocytes: dose-dependent effect of deoxycholic acid | The International Liver Congress European Association for the Study of the Liver
European Association for the Study of the Liver (Barcelona, Spain)
|
2011 | Increased expression of miR-34 in NAFLD patients and targeting by ursodeoxycholic acid in rat liver | 19th United European Gastroenterology Week
United European Gastroenterology (Estocolmo, Sweden)
|
2009 | Modulation of the p53-ubiquitin-proteasome degradation pathway by ursodeoxycholic acid | 44th Annual Meeting of the European Association for the Study of the Liver
European Association for the Study of the Liver (Copenhaga, Denmark)
|
2007 | Antiapoptotic effect of ursodeoxycholic acid in hepatocytes. | Falk Research Workshop
Falk Foundation (Goettingen, Germany)
|
2007 | Differential regulation of cyclin D1 and apoptosis by bile acids in primary rat hepatocyte | 42st Meeting of the European Association for the Study of Liver Diseases
European Association for the Study of the Liver (Barcelona, Spain)
|
2005 | Targeting apoptosis in neurologic disorders. | 4th International Congress on Vascular Dementia
(Porto, Portugal)
|
2004 | Tauroursodeoxycholic acid, a bile acid with in vivo anti-apoptotic and neuroprotective properties. | XVIII International Bile Acid Meeting
Falk Foundation (Estocolmo, Sweden)
|
2004 | Rodrigues CMP. Targeting apoptosis in human diseases. | 26th European Society of Parental and Enteric Nutrition
European Society of Parental and Enteric Nutrition (Lisboa, Portugal)
|
2004 | Mechanisms of cell death in steatohepatitis – Apoptosis or necrosis? | EASL NASH Monothematic Conference
European Association for the Study of the Liver (Lisboa, Portugal)
|
2004 | Enhanced apoptosis and Bcl-2 protein production in the liver of patients with steatohepatitis | 39th Meeting of the European Association for the Study of Liver Diseases
European Association for the Study of the Liver (Berlim, Germany)
|
2003 | Ursodeoxycholic acid prevents TGF-ß1-induced apoptosis through modulation of the glucocorticoid receptor in primary rat hepatocytes | 54th Annual Meeting of the American Association for the Study of Liver Diseases
American Association for the Study of Liver Diseases (Chicago, United States)
|
2002 | Tauroursodeoxycholic acid for the treatment of acute and chronic neurodegenerative diseases. | XVII International Bile Acid Meeting
Falk Foundation (Freiburgo, Germany)
|
2000 | Inhibition of apoptosis in a rat model of Huntington’s disease using tauroursodeoxycholate. | XVI International Bile Acid Meeting
Falk Foundation (Haia, Netherlands)
|
2000 | Tauroursodeoxycholate prevents mitochondrial membrane perturbation induced by recombinant Bax protein | 51st Annual Meeting of the American Association for the Study of Liver Diseases
American Association for the Study of Liver Diseases (Chicago, United States)
|
2000 | Apoptosis induced by deoxycholic acid, unconjugated bilirubin and amyloid ß-peptide reflects mitochondrial perturbation which may be inhibited by ursodeoxycholic acid | 35th Annual Meeting of the European Association for the Study of the Liver
European Association for the Study of the Liver (Roterdão, Netherlands)
|
1999 | Ursodeoxycholic acid inhibits apoptosis by modulating depolarization and channel-forming activity of the mitochondrial membrane | 34th Annual Meeting of the European Association for the Study of the Liver
European Association for the Study of the Liver (Nápoles, Italy)
|
1998 | Bile acid pattern in meconium is influenced by cholestasis of pregnancy and not altered after ursodeoxycholic acid therapy | 49th Annual Meeting of the American Association for the Study of Liver Diseases
American Association for the Study of Liver Diseases (Chicago, United States)
|
1997 | A novel role for ursodeoxycholic acid in modulating apoptosis in rat liver, isolated hepatocytes and human hepatoma cells | 48th Annual Meeting of the American Association for the Study of Liver Diseases
American Association for the Study of Liver Diseases (Chicago, United States)
|
1994 | Tauroursodeoxycholic acid (TUDCA) appears more effective than UDCA at displacing hydrophobic bile acids from the bile acid pool of patients with primary biliary cirrhosis | 45th Annual Meeting of the American Association for the Study of Liver Diseases
American Association for the Study of Liver Diseases (Chicago, United States)
|
Supervision
Thesis Title Role |
Degree Subject (Type) Institution / Organization |
|
---|---|---|
2020/01/01 - Current | Total of ca. 150 postgraduate student and postdoc supervisions (50 PhD students; 80 MSc students; 13 Postdocs)
Supervisor
|
|
2020 - 2023 | Targeting superficial tumors using a nanotechnological hybrid approach
Co-supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2020 - 2023 | Development of new necroptosis inhibitors: targeting RIP1 kinase
Co-supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2019 - 2023 | Emerging Biomarkers, Targets and Therapies for Non-alcoholic Fatty Liver Disease
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2018 - 2022 | Innovative Therapies and Technologies in Cancer
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2017 - 2021 | Emerging inflammatory mediators as predictors of oocyte quality and IVF ART (assisted reproduction techniques) treatment outcome:
from biochemical markers to clinic
Co-supervisor
|
Ciências Farmacêuticas (PhD)
Universidade do Porto Faculdade de Farmácia, Portugal
|
2017 - 2021 | Aromatase inhibitors in breast cancer: drug discovery and strategies to overcome acquired resistance
Co-supervisor
|
Ciências Farmacêuticas
Universidade do Porto Faculdade de Farmácia, Portugal
|
2017 - 2021 | New Drugs to Target Neurodegeneration and Neuroinflammation in Parkinson’s Disease
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2017 - 2021 | Design, synthesis and biological evaluation of novel p53 activators by targeting p53 protein-protein interactions
Co-supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2017 - 2021 | Response to neoadjuvant chemoradiation in rectal cancer. A study on clinical and molecular predictors of response
Co-supervisor
|
Medicina (PhD)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
|
2017 - 2021 | Tetraoxane-based tumor-activated prodrug strategy to target intracellular labile ferrous iron
Co-supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2017 - 2021 | miRNA Markers and Cell Death in NAFLD Progression
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2019 - 2020 | Targeting of mitofusin-2 by microRNAs in non-alcoholic fatty liver disease
Co-supervisor
|
Farmácia (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2019 - 2020 | Therapeutic targeting of microRNA-21 and bile acid-activated receptors in non-alcoholic fatty liver disease
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2019 - 2020 | Role of adipose tissue-derived extracellular vesicles on liver cells under steatogenic conditions”, sob orientação de Rui
Castro.
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2019 - 2020 | Bioenergetic Regulation of Neural Stem Cell Secretome: a Novel Therapeutic Opportunity for Neurodegeneration
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2016 - 2020 | New Drugs to Treat Fatty Liver and Progression to Cancer
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2016 - 2020 | Development and application of an innovative disposable sensor
for Novel Psychoactive Substances (NPSs) based on electrochemistry
Co-supervisor
|
Ciências Farmacêuticas (PhD)
Universidade do Porto Faculdade de Farmácia, Portugal
|
2018 - 2019 | Quality and Reporting of Clinical Practice Guidelines on the Management of Parkinson’s Disease
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2015 - 2019 | Probing and Targeting Mitochondria Bioenergetics in Neurodegeneration
Co-supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2015 - 2019 | Role of Mitofusin 2 in Non-alcoholic Fatty Liver Disease and Targeting by microRNAs
Co-supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2015 - 2019 | Systems Analysis of Inflammation and Neuronal Demise in Neurodegenerative Diseases
Co-supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2015 - 2019 | Neuroprotection by histone acetyltransferase modulators: activation or inhibition?
Co-supervisor
|
Ciências Farmacêuticas (PhD)
Universidade do Porto Faculdade de Farmácia, Portugal
|
2014 - 2019 | Exploring MEK5-ERK5 Signaling in Colorectal Cancer: A Therapeutic Target for Chemosensitization
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2017 - 2018 | Role of the miR-21/MAPK signaling pathway and bile acid-activated receptors in non-alcoholic fatty liver disease progression
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2017 - 2018 | Biological effects of phytocannabinoids and endocannabinoids on ER+ breast cancer cells
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2017 - 2018 | Discovering New Molecules for Non-toxic Differentiation Therapy in Cancer
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2017 - 2018 | Evaluating alterations in adenosine metabolism and function responsible for brown adipose tissue deregulation: Implications
in obesity
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2017 - 2018 | High Throughput Screening of Cell Fate Modulators Using Colon Cancer Stem Cells: Assay Development
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2017 - 2018 | Targeting mitochondria-nucleus communication to improve agEing-impaired neurogenesis
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2010 - 2018 | Programmed Cell Death in Influenza Virus Sub-types
Co-supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2016 - 2017 | Necroptosis and mitochondrial dysfunction in NAFLD: potential novel modulators
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2016 - 2017 | The role of mitochondrial adaptations in the acquistion of the phenotype induced by LDL-cholesterol in breast cancer
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2016 - 2017 | Role of Mi-2/NuRD in chromatin regulation to regulate neural stem cell fate and life-span in Drosophila melanogaster
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2015 - 2017 | Lectins in Mediterranean flora. Evalutation of antitumor activity on HT29 colon cancer cells
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2013 - 2017 | Targeting Hepatocyte Necroptosis to Treat Liver Diseases
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2013 - 2017 | miR-143, -145 and -21 Modulation in Colon Cancer - from Anticancer Activity to Drug Sensitization
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2013 - 2017 | Targeting of miR-21 and Bile Acid Activated Receptors in Non-alcoholic Fatty Liver Disease
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2015 - 2016 | Targeting microglia necroptosis to arrest neuroinflammation
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2015 - 2016 | Screening of necroptosis modulators with potential therapeutic application
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2015 - 2016 | Molecular insights into the role of alpha-synuclein phosphorylation in synucleinophathies
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2015 - 2016 | Spirooxadiazoline oxindoles as potential anticancer agents
Co-supervisor
|
Química Farmacêutica e Terapêutica (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2015 - 2016 | Targeting MicroRNAs for Modulation of the Anti-Tumor Human gd T Cell Differentiation
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2013 - 2016 | Efeitos do tratamento com N-acetilcisteina sob o défice cognitivo induzido por estreptozotocina em camundongos
Co-supervisor
|
Universidade Federal de Santa Maria, Brazil
|
2012 - 2015 | Novel Therapeutic Targets in Colon Cancer
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2012 - 2015 | Fine-Tuning Neurogenesis: miRNA Regulatory Networks
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2012 - 2015 | Control of Neuronal Signalling Pathways by CYP46A1, an Enzyme Involved in Brain Cholesterol Homeostasis
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2011 - 2015 | Design and Synthesis of Small Molecule Modulators of p53
Co-supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2013 - 2014 | Using TUDCA to Treat AD Pathology in APP/PS1 Mice after Disease Onset
Supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2013 - 2014 | Inhibition of Mutant KRAS Transcription in Human Cancer
Supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2010 - 2014 | A New Regulatory Mechanism Involving p53 in JMJD3-mediated Neurogenesis
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2012 - 2013 | Exploring the Role of MEK5/ERK5 Signaling in Colon Cancer and Sensitivity to 5 Fluorouracil
Supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2009 - 2013 | Avaliação do efeito neuroprotetor do p, p’-dimetoxil disseleneto de difenila em modelos de demência decorrentes da Doença
de Alzheimer em roedores: Estudo dos mecanismos envolvidos
Co-supervisor
|
Universidade Federal de Santa Maria, Brazil
|
2009 - 2013 | Apoptosis and miRNAs in Non-Alcoholic Fatty Liver Disease Pathogenesis
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2011 - 2012 | Creatine Protects Against Rotenone-induced Cell Death of Cerebellar Granule Neurons
Co-supervisor
|
Ciências Biofarmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2009 - 2012 | Amyloid ß Peptide and p63: Two Prime Triggers of Neural Apoptosis and Differentiation
Supervisor
|
Neurociências (PhD)
Universidade de Lisboa Faculdade de Medicina, Portugal
|
2008 - 2012 | Regulation of Neural Stem Cell Proliferation by Apoptosis-relevant Factors
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2008 - 2012 | Endogenous Regulatory Circuits Controlled by CYP46A1: Role of 24S-hydroxycholestreol on Small GTPase Activity and its Relation
to Neurodegenerative Disorders with Altered Brain Cholesterol Metabolism
Co-supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2010 - 2011 | Exploring Antibody-mediated Small RNA Delivery as a Therapeutic Approach in Colon Cancer
Supervisor
|
Bioquímica (Master)
Universidade de Lisboa Faculdade de Ciências, Portugal
|
2007 - 2011 | Apoptosis Signaling Associated with Amyloid beta-induced Cellular Dysfunction and Degeneration: Relevance for Alzheimer's
disease
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2006 - 2010 | Role of Apoptosis Factors during Mouse Neural Stem Cell Differentiation
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2005 - 2009 | Role of Apoptosis and miRNAs in Identifying Novel Therapeutic Targets in Colon Cancer
Supervisor
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2004 - 2008 | p53, a Novel Molecular Target of Ursodeoxycholic Acid in Modulating Hepatocyte Apoptosis
Supervisor of Joana Amaral
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2006 - 2007 | Potential Role of Apoptosis During Neural Stem Cell Differentiation
Supervisor
|
Università degli Studi di Milano-Bicocca, Italy
|
2003 - 2007 | Signaling Events in Tauroursodeoxycholic Acid Protection of Amyloid beta-peptide-induced Neuronal Death
Supervisor of Rita Ramalho
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2002 - 2006 | Tauroursodeoxycholic Acid Protection of Stroke: Targeting Cell Survival Cascades
Supervisor of Rui Castro
|
Farmácia (PhD)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2001 - 2005 | Modulation of Hepatocyte Apoptosis by Ursodeoxycholic Acid: Role of Nuclear Steroid Receptors
Supervisor of Susana Solá
|
Farmácia
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
Event organisation
Event name Type of event (Role) |
Institution / Organization | |
---|---|---|
2018 - 2018 | Basic Science Seminar “Targetable pathways in liver disease”, International Liver Congress 2018, European Association for
the Study of the Liver (EASL), Paris, France (2018 - 2018)
Seminar
|
European Association for the Study of the Liver, Switzerland |
2016 - 2016 | International Liver Congress 2016, European Association for the Study of the Liver (EASL), Barcelona, Spain (2016 - 2016)
Congress (Co-organisor)
|
European Association for the Study of the Liver, Switzerland |
2016 - 2016 | Basic Science Seminar “Gut-liver Axis”, International Liver Congress 2016, European Association for the Study of the Liver
(EASL), Barcelona, Spain (2016 - 2016)
Seminar (Co-organisor)
|
European Association for the Study of the Liver, Switzerland |
2016 - 2016 | Joint Workshop “EASL-Cochrane Hepato-Biliary Group”, International Liver Congress 2016, European Association for the Study
of the Liver, Barcelona, Spain (2016 - 2016)
Workshop (Co-organisor)
|
|
2016 - 2016 | XIX Congresso Nacional de Bioquímica, da Sociedade Portuguesa de Bioquímica, Guimarães, Portugal (2016 - 2016)
Congress (Member of the Scientific Committee)
|
Sociedade Portuguesa de Bioquímica, Portugal |
2015 - 2015 | The International Liver Congress 2015, European Association for the Study of the Liver (EASL), Vienna, Austria. (2015 - 2015)
Congress
|
European Association for the Study of the Liver, Switzerland |
2015 - 2015 | EASL-FLIP Joint Workshop on Advances in pathogenesis, diagnosis and clinical hotspots, International Liver Congres 2015, European
Association for the Study of the Liver. International Liver Congress, Vienna, Austria. (2015 - 2015)
Workshop (Co-organisor)
|
|
2015 - 2015 | Seminar “Young Investigator Seminar – Liver Cell Death", International Liver Congress 2015, European Association for the Study
of the Liver, Vienna, Austria. (2015 - 2015)
Seminar (Co-organisor)
|
European Association for the Study of the Liver, Switzerland |
2014 - 2014 | The International Liver Conggress, European Association for the Study of the Liver (EASL), London, UK, 2014 (2014 - 2014)
Congress (Co-organisor)
|
European Association for the Study of the Liver, Switzerland |
2014 - 2014 | EASL-I-PSC-SG (International PSC Study Group) Joint Workshop, International Liver Congress 2014, European Association for
the Study of the Liver., London, UK. (2014 - 2014)
Workshop (Co-organisor)
|
European Association for the Study of the Liver, Switzerland |
2013 - 2013 | Translational Workshop “Modulation of Liver Injury and Metabolism Through Bile Acid Receptors”, International Liver Congress
of the European Association for the Study of the Liver 2013, Amsterdam, Holland. (2013 - 2013)
Workshop (Co-organisor)
|
European Association for the Study of the Liver, Switzerland |
2010 - 2010 | Simpósio “Redox, Stress and Cell Death”, XVII Congresso Nacional de Bioquímica 2010, Porto, Portugal (2010 - 2010)
Symposium (Member of the Scientific Committee)
|
Sociedade Portuguesa de Bioquímica, Portugal |
2006 - 2006 | Simpósio “Neurobiologia”, Congresso Nacional de Bioquímica 2006, Aveiro, Portugal (2006 - 2006)
Symposium (Member of the Scientific Committee)
|
Sociedade Portuguesa de Bioquímica, Portugal |
2004 - 2004 | Simpósio “Neuroquímica”, XIV Congresso Nacional de Bioquímica 2004, Vilamoura, Portugal (2004 - 2004)
Symposium (Member of the Scientific Committee)
|
Sociedade Portuguesa de Bioquímica, Portugal |
1998 - 1998 | Symposium “Update on bilirubin errors and new therapies”, 33rd Annual Meeting of the European Association for the Study of
the Liver 1998, Lisbon, Portugal (1998 - 1998)
Symposium (Member of the Organising Committee)
|
European Association for the Study of the Liver, Switzerland |
Jury of academic degree
Topic Role |
Candidate name (Type of degree) Institution / Organization |
|
---|---|---|
2020/01/01 | Total of ca. 220 MSc juries (president in >175); 120 PhD juries (main opponent in >100); 15 Habilitation juries (main opponent in 14) | (Other) |
2020 | Provas de Agregação em Biologia Experimental e Biomedicina, especialidade em Biologia Molecular, Celular e do Desenvolvimento
(Thesis) Main arguer
|
Paulo Oliveira (Aggregation)
Universidade de Coimbra Instituto de Investigação Interdisciplinar, Portugal
|
2020 | Targeting metabolism for resolving Non-Alcoholic Steatohepatitis
(Thesis) Main arguer
|
Jorge Simon Espinosa (PhD)
Universidad del País Vasco, Spain
|
2019 | Provas de Agregação em Biociências, especialidade de Bioquímica
(Thesis) Main arguer
|
Rui Carvalho (Aggregation)
Universidade de Coimbra Faculdade de Ciencias e Tecnologia, Portugal
|
2019 | Identification of a new genetic defect in bile acid synthesis: ACOX2 partial deficiency. Molecular bases, pathophysiology
and implication in idiopathic hepatocellular disease
(Thesis) Main arguer
|
Marta Alonso Pena (PhD)
Universidad de Salamanca, Spain
|
2019 | Responses to liver damage: macrophage plasticity in tissue recovery and dysbiotic drifts
(Thesis) Main arguer
|
Inês Coelho (PhD)
Universidade Nova de Lisboa Instituto de Tecnologia Química e Biológica, Portugal
|
2019 | Pathophysiology of doxorubicin cardiotoxicity: from mitochondrial homeostasis to biological clocks
(Thesis) Main arguer
|
Luciana Ferreira (PhD)
Universidade de Coimbra Faculdade de Farmácia, Portugal
|
2018 | Molecular mechanisms of bile acid-induced apoptosis and cytoprotection
(Thesis) Main arguer
|
Tânia Sousa (PhD)
Universidade de Lisboa Instituto Superior Técnico, Portugal
|
2018 | Phenotypes in Inflammatory Bowel Disease
(Thesis) Main arguer
|
Joana Torres (PhD)
Universidade de Lisboa Faculdade de Medicina, Portugal
|
2018 | The Role of Post-Translational Modifications on the Oligomerization, Aggregation and Toxicity of Mutant Huntingtin
(Thesis) Main arguer
|
Joana Santos (PhD)
Universidade de Lisboa Faculdade de Medicina, Portugal
|
2018 | Gold nanoparticles for nanotheranostics in leukemia – Addressing chronic myeloid leukemia
(Thesis) Main arguer
|
Raquel Vinhas (PhD)
Universidade Nova de Lisboa Faculdade de Ciências e Tecnologia, Portugal
|
2017 | Provas de Agregação em Farmácia, especialidade de Biologia Celular e Molecular
(Thesis) Main arguer
|
Isabel Carvalho (Aggregation)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2017 | Provas de Agregação em Farmácia, especialidade de Bioquímica
(Thesis) Main arguer
|
Liliana Silva (Aggregation)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2016 | Provas de Agregação, em Biologia Celular e Molecular
(Thesis) Main arguer
|
Elsa Bronze (Aggregation)
Universidade do Porto Faculdade de Farmácia, Portugal
|
2013 | Provas de Agregação em Bioquímica, na especialidade de Bioquímica Estrutural
(Thesis) Main arguer
|
Cláudio Gomes (Aggregation)
Universidade Nova de Lisboa Instituto de Tecnologia Química e Biológica, Portugal
|
2012 | Provas de Agregação em Farmácia, na especialidade de Biologia Celular e Molecular
(Thesis) Main arguer
|
Alexandra Brito (Aggregation)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2011 | Provas de Agregação em Farmácia, na especialidade de Bioquímica
(Thesis) Main arguer
|
Graça Soveral (Aggregation)
Universidade de Lisboa Faculdade de Farmácia, Portugal
|
2010 | Provas de Agregação em Ciências da Saúde, na especialidade de Ciências Biomédicas
(Thesis) Main arguer
|
Cristina Rego (Aggregation)
Universidade de Coimbra Faculdade de Medicina, Portugal
|
Association member
Society Organization name | Role | |
---|---|---|
2013 - Current | Vice-presidente, FARM-ID - Associação da Faculdade de Farmácia para I&D | Vice-Presidente |
1999 - Current | Member, American Association for the Study of Liver Diseases | Member |
2013 - 2016 | Governing Board, European Association Study of the Liver (EASL) | Governing Board Member (Scientific Committee) |
2007 - 2011 | Direção, Sociedade Portuguesa de Hepatologia | Membro da Direção |
2003 - 2011 | Direção, Sociedade Portuguesa de Neurociências | Membro da Direção |
Committee member
Activity description Role |
Institution / Organization | |
---|---|---|
2009 - Current | Membro, Conselho Científico da Faculdade de Farmácia, Universidade de Lisboa
Member
|
Universidade de Lisboa Faculdade de Farmácia, Portugal |
2013 - 2016 | Membro, Conselho Científico das Ciências da Vida e da Saúde, Fundação para a Ciência e a Tecnologia (FCT), Portugal
Member
|
Fundação para a Ciência e a Tecnologia, Portugal |
2013 - 2016 | Chair, Basic Science Concerted Action Group, European Association for the Study of the Liver
Coordinator
|
European Association for the Study of the Liver, Switzerland |
2014 - 2015 | Vice-presidente, Conselho Científico da Faculdade de Farmácia, Universidade de Lisboa
President / Vice-president
|
Universidade de Lisboa Faculdade de Farmácia, Portugal |
2010 - 2013 | Membro, Comissão Executiva, Instituto de Investigação do Medicamento e Ciências Farmacêuticas
Member
|
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal |
Consulting
Activity description | Institution / Organization | |
---|---|---|
2014 - Current | Scientific Committee on Biosciences member, Santa Casa da Misericórdia de Lisboa | Santa Casa da Misericórdia de Lisboa, Portugal |
2011 - Current | Scientific Advisory Board member, Metselex, Inc., USA | |
2014 - 2016 | Basic Science Concerted Action Group chair, European Association for the Study of the Liver | European Association for the Study of the Liver, Switzerland |
2013 - 2014 | Basic Science Concerted Action Group member, European Association for the Study of the Liver | European Association for the Study of the Liver, Switzerland |
2005 - 2011 | Scientific Advisory Board member, SMG Therapeutics, Inc., USA |
Course / Discipline taught
Academic session | Degree Subject (Type) | Institution / Organization | |
---|---|---|---|
2020 - Current | Seminários/Seminars I - da Descoberta ao Uso do Medicamento | Ciências Farmacêuticas (Mestrado integrado) | Universidade de Lisboa Faculdade de Farmácia, Portugal |
2014 - Current | Coordenador, Doutoramento em Farmácia | Farmácia (Doutoramento) | Universidade de Lisboa Faculdade de Farmácia, Portugal |
2014 - Current | Biomarcadores e Tecnologias Moleculares/Molecular Biomarkers and Technologies | Farmácia (Doutoramento) | Universidade de Lisboa Faculdade de Farmácia, Portugal |
2010 - Current | Coordenador, Mestrado em Ciências Biofarmacêuticas | Ciências Biofarmacêuticas (Mestrado) | Universidade de Lisboa Faculdade de Farmácia, Portugal |
2010 - Current | Sinalização Celular/Cell Sinalling | Ciências Biofarmacêuticas (Mestrado) | Universidade de Lisboa Faculdade de Farmácia, Portugal |
2010 - Current | Oncobiologgia/Oncobiology | Ciências Biofarmacêuticas (Mestrado) | Universidade de Lisboa Faculdade de Farmácia, Portugal |
1999 - Current | Bioquímica II/Biochemistry II | Ciências Farmacêuticas (Mestrado integrado) | Universidade de Lisboa Faculdade de Farmácia, Portugal |
2014 - 2022 | Diretor, FCT PhD Programme in Medicines and Pharmaceutical Innovation (i3DU) | FCT PhD Programme in Medicines and Pharmaceutical Innovation (i3DU) (Doctor of Philosophy) | Universidade de Lisboa Faculdade de Farmácia, Portugal |
Evaluation committee
Activity description Role |
Institution / Organization | Funding entity | |
---|---|---|---|
2014 - Current | Research projects, Agence Nationale de la Recherche
Evaluator
|
Agence nationale de la recherche, France | Agence nationale de la recherche |
2018 - 2020 | Research Consortia and Projects (LiSyM – Systems Medicine of the Liver), Federal Ministry of Finance - BMBF, Germany
Evaluator
|
Bundesministerium der Finanzen, Germany | Bundesministerium der Finanzen |
2019 - 2019 | Research Projects (Biological and Medical Sciences), Austrian Science Fund
Evaluator
|
Fonds zur Förderung der wissenschaftlichen Forschung, Austria | Fonds zur Förderung der wissenschaftlichen Forschung |
2017 - 2017 | ERC Consolidator Grants, EU European Comission H2020
Specialist
|
European Research Council, Belgium | European Research Council |
2009 - 2017 | Postdoc and PhD fellowships, Fundação para a Ciência e a Tecnologia
Evaluator
|
Fundação para a Ciência e Tecnologia, Portugal | Fundação para a Ciência e Tecnologia |
2013 - 2016 | Research fellowships (Post-doc, Physician Scientists, Entry-level, Short-term) and Mentorships, European Association for
the Study of the Liver
Evaluator
|
European Association for the Study of the Liver, Switzerland | European Association for the Study of the Liver |
2015 - 2015 | Research Perojects, Worldwide Cancer Research, UK
Evaluator
|
Worldwide Cancer Research, United Kingdom | Worldwide Cancer Research |
2015 - 2015 | Research Projects, Centres of Excellence in Neurodegenerative disease (CoEN) Initiative | Deutsches Zentrum für Neurodegenerative Erkrankungen, Germany | Deutsches Zentrum für Neurodegenerative Erkrankungen |
2008 - 2015 | Research projects, Wellcome Trust, UK
Evaluator
|
Wellcome Trust, United Kingdom | Wellcome Trust |
2014 - 2014 | European research projects for Cross-Disease Analysis of Pathways related to Neurodegenerative Diseases, EU Joint Programme
Neurodegenerative Disease Research (JPND)
Evaluator
|
EU Joint Programme Neurodegenerative Disease Research, Germany | EU Joint Programme Neurodegenerative Disease Research |
2012 - 2014 | Research projects, Alzheimer's Association, USA
Evaluator
|
Alzheimer's Association, United States | Alzheimer's Association |
2013 - 2013 | European research projects on Genetic, Epigenetic and Environmental Risk Factors, European Joint Programme Neurodegenerative
Disease Research
Evaluator
|
EU Joint Programme Neurodegenerative Disease Research, Germany | EU Joint Programme Neurodegenerative Disease Research |
2013 - 2013 | Investigador FCT, Fundação para a Ciência e a Tecnologia
Evaluator
|
Fundação para a Ciência e a Tecnologia, Portugal | Fundação para a Ciência e a Tecnologia |
2012 - 2012 | Research projects, Research Foundation Flanders, Brussels | Fonds Wetenschappelijk Onderzoek Vlaanderen, Belgium | Fonds Wetenschappelijk Onderzoek Vlaanderen |
Distinctions
Award
2023 | Mulheres na Ciência 2023
Ciência Viva, Portugal
|
2022 | 2022 Sir Hans Krebs medal from FEBS |
2016 | University of Lisbon Scientific Prize (Biomedical Sciences) |
2003 | Francisco Pulido Valente Science Award (Neurosciences)
Fundação para a Ciência e a Tecnologia, Portugal
|
2000 | European Society for Pediatric Research Young Investigator Award |
2000 | European Association for the Study of the Liver Sheila Sherlock Award (Hepatology)
European Association for the Study of the Liver, Switzerland
|
1999 | European Association for the Study of the Liver Young Investigator Award
European Association for the Study of the Liver, Switzerland
|
1992 | Ordem dos Farmacêuticos Academic Merit Honour
Ordem dos Farmaceuticos, Portugal
|
Other distinction
2021 | Associate editor, Hepatology |
2019 | Editorial Board member, Journal of Hepatology |
2019 | Editorial Board member, Biomolecules (Chemical Biology section) |
2019 | Executive Editor, Journal of Physiology and Biochemistry |
2016 | Editorial Board member, Frontiers in Neuroscience (Neurodegeneration section) |
2014 | Editorial Board member (Founding Editor), Cell Stress |
2011 | Editorial Board member, Frontiers in Pharmacology (Experimental Pharmacology section) |
2010 | Associate Editor, Clinics and Research in Hepatology and Gastroenterology |
2010 | Associate Editor, Journal of Alzheimer's Disease |
2004 | Portuguese Nomination for the European Young Investigator Award
Fundação para a Ciência e a Tecnologia, Portugal
|